MedPath
HSA Approval

BUTYLIN SYRUP 1.5 mg/5 ml

SIN08075P

BUTYLIN SYRUP 1.5 mg/5 ml

BUTYLIN SYRUP 1.5 mg/5 ml

March 18, 1995

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R03CC03

terbutaline

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

HOVID BHD

Active Ingredients

TERBUTALINE SULPHATE

1.5 mg/5 ml

Terbutaline

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.